Get started
Author

Abdallah Ennaji

Observed name: ABDALLAH ENNAJI
ORCID: 0009-0008-9284-4476
Observed ORCID: 0009-0008-9284-4476
OpenAlex ID: A5057662121
LH pulsatile secretion and testosterone blood levels are influenced by sexual arousal in human males
1993 · Serge G. Stoléru, Abdallah Ennaji, et al. · Psychoneuroendocrinology · 95
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial
2023 · Yungan TAO, Xu-Shan Sun, et al. · European Journal of Cancer · 64
PDF
Immunogenicity and Safety of Berna-yf Compared With Two Other 17d Yellow Fever Vaccines in a Phase 3 Clinical Trial
2005 · MARKUS PFISTER, OLIVER KÜRSTEINER, et al. · American Journal of Tropical Medicine and Hygiene · 50
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al. · Clinical Cancer Research · 15
PDF
Supplementary Table S2 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S5 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Figure S2 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Methods S1 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S1 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S12 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S4 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S7 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S3 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S8 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S6 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S10 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Figure S1 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Data from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S11 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S13 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S9 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Works count: 21
Citation count: 224
H-index: 4
I10-index: 4
Year
Topic
Type